
Uppsala Reports editor
@UMCGlobalSafety
Research / 23 February 2023
In this digital age, can pharmacovigilance experts leverage on new types of data to find evidence for signals? Listen to the latest Drug Safety Matters podcast to find out.
Spontaneous adverse drug reaction reports have been the proverbial ‘bread and butter’ for signal detection since the beginnings of pharmacovigilance. But times are changing, and with the abundance of data now available in a society that has gone digital, it is time to explore new data sources to detect signals.
Join Federica Santoro and Daniele Sartori, a pharmacovigilance scientist at UMC and doctoral researcher at the University of Oxford, discuss expanding sources of evidence for more reliable signal detection.
Subscribe by visiting the Drug Safety Matters website or listen to the podcast here:
AI holds potential to transform pharmacovigilance. But navigating the risks requires critical assessment. This article explores AI's evolving role in medicines safety.
Research / 22 October 2024
To tackle the lack of medicine and vaccine safety data for pregnant people, UMC has developed an algorithm to more easily identify pregnancy-related reports in VigiBase.
Research / 21 January 2025
The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.
Research / 07 October 2024